Provided by Tiger Trade Technology Pte. Ltd.

Viridian Therapeutics, Inc.

31.60
-0.5300-1.65%
Post-market: 31.600.00000.00%19:16 EST
Volume:1.55M
Turnover:49.13M
Market Cap:3.02B
PE:-10.46
High:32.27
Open:32.15
Low:31.20
Close:32.13
52wk High:34.04
52wk Low:9.90
Shares:95.44M
Float Shares:80.72M
Volume Ratio:1.14
T/O Rate:1.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.0205
EPS(LYR):-3.0722
ROE:-49.89%
ROA:-30.08%
PB:9.60
PE(LYR):-10.29

Loading ...

Viridian Therapeutics Announces Successful October Submission of Biologics License Application (Bla) to U.S. FDA for Veligrotug in Thyroid Eye Disease

THOMSON REUTERS
·
Nov 03

13D Filings -- Barrons.com

Dow Jones
·
Nov 01

What Viridian Therapeutics (VRDN)'s Major Financing and Revenue-Sharing Deal Means for Shareholders

Simply Wall St.
·
Oct 29

Fairmount Funds Management LLC Reports Acquisition of Viridian Therapeutics Common Shares

Reuters
·
Oct 28

Viridian Therapeutics Advances VRDN-003 Study for Thyroid Eye Disease

TIPRANKS
·
Oct 28

Analysts Offer Insights on Healthcare Companies: Celcuity (CELC) and Viridian Therapeutics (VRDN)

TIPRANKS
·
Oct 22

Viridian Therapeutics Announces Pricing Of $251 Million Public Offering Of Shares Of Common Stock

Reuters
·
Oct 22

Viridian Therapeutics Inc: Selling a Total of 11.4 Mln Shares of Common Stock at a Price of $22 per Share

THOMSON REUTERS
·
Oct 22

BUZZ-Viridian Therapeutics dips on planned stock deals

Reuters
·
Oct 22

BRIEF-Viridian Therapeutics Announces Proposed Underwritten Public Offering

Reuters
·
Oct 22

Viridian Therapeutics Reports Preliminary $490.9 Million in Cash and Securities for Q3 2025

Reuters
·
Oct 22

Viridian Therapeutics Launches Underwritten Public Offering of Common and Preferred Stock

Reuters
·
Oct 22

Viridian Therapeutics enters royalty financing agreement with DRI Healthcare

TIPRANKS
·
Oct 20

BRIEF-Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million

Reuters
·
Oct 20

Viridian Therapeutics Secures Up to $300 Million in Amended Credit Facility with Hercules Capital

Reuters
·
Oct 20

Viridian Therapeutics Announces Royalty Financing With Dri Healthcare for up to $300 Million

THOMSON REUTERS
·
Oct 20

Viridian Therapeutics - Proceeds of Financing Expected to Fully Fund Anticipated Commercial Launches of Both Veligrotug and Vrdn-003

THOMSON REUTERS
·
Oct 20

Viridian Therapeutics Inc - Amends Credit Facility With Hercules Capital

THOMSON REUTERS
·
Oct 20

Viridian Therapeutics Inc - Veligrotug Bla Submission Expected Imminently

THOMSON REUTERS
·
Oct 20

Press Release: DRI Healthcare Trust Announces Acquisition of a Synthetic Royalty Interest in the U.S. Sales of Veligrotug and VRDN-003 for the Treatment of Thyroid Eye Disease (TED)

Dow Jones
·
Oct 20